Publicacions
Berberina i els seus derivats
La berberina és un compost alcaloid aïlat d'herbes medicinals i que mostra una activitat farmacològica diversa. Encara que les bases moleculars de la seva activitat biològica continuen essent objecte de debat, es continua acumulant informació sobre la molècula, dades que seran aprofitades per a futures aplicacions a la clínica. Entre les aplicacions terapèutiques que han obert millors expectatives i interès per part dels científics destanquen les relacionades amb malaltia cardiovascular, la síndrome metabòlica i el càncer. Malgrat aquesta activitat, la seva baixa absorció i biodisponibilitat limite el seu ús terapèutic per lo que en els darrers anys s'han dissenyat nous derivats que milloran les seves propietats farmacològiques, per avançar en el seu ús a la clínica.
Publicacions rellevants en l'àrea de recerca
08/04/2024
Clonal gene signatures predict prognosis in mesothelioma and lung adenocarcinoma.
Lin Y, Burt BM, Lee HS, Nguyen TT, Jang HJ, Lee C, Hong W, Ripley RT, Amos CI, Cheng C.
NPJ Precis Oncol. Feb 2024.
Malignant pleural mesothelioma (MPM) is a rare but lethal pleural cancer with high intratumor heterogeneity (ITH). A recent study in lung adenocarcinoma has developed a clonal gene signature (ORACLE) from multiregional transcriptomic data and demonstrated... see publication
05/04/2023
Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity.
Mangiante L, Alcala N, Sexton-Oates A, Di Genova A, Gonzalez-Perez A, Khandekar A, Bergstrom EN, Kim J, Liu X, Blazquez-Encinas R, Giacobi C, Le Stang N, Boyault S, Cuenin C, Tabone-Eglinger S, Damiola F, Voegele C, Ardin M, Michallet MC, Soudade L, Delhomme TM, Poret A, Brevet M, Copin MC, Giusiano-Courcambeck S, Damotte D, Girard C, Hofman V, Hofman P, Mouroux J, Cohen C, Lacomme S, Mazieres J, de Montpreville VT, Perrin C, Planchard G, Rousseau N, Rouquette I, Sagan C, Scherpereel A, Thivolet F, Vignaud JM, Jean D, Ilg AGS, Olaso R, Meyer V, Boland-Auge A, Deleuze JF, Altmuller J, Nuernberg P, Ibáñez-Costa A, Castaño JP, Lantuejoul S, Ghantous A, Maussion C, Courtiol P, Hernandez-Vargas H, Caux C, Girard N, Lopez-Bigas N, Alexandrov LB, Galateau-Salle F, Foll M, Fernandez-Cuesta L.
Nat Genet. Mar 2023. doi: 10.1038/s41588-023-01321-1.
Malignant pleural mesothelioma (MPM) is an aggressive cancer with rising incidence and challenging clinical management. Through a large series of whole-genome sequencing data, integrated with transcriptomic and epigenomic data using multiomics factor... see publication
16/11/2022
Multi-Target Potential of Berberine as an Antineoplastic and Antimetastatic Agent: A Special Focus on Lung Cancer Treatment.
Achi IT, Sarbadhikary P, George BP, Abrahamse H.
Cells. Oct 2022.
Despite therapeutic advancements, lung cancer remains the principal cause of cancer mortality in a global scenario. The increased incidence of tumor reoccurrence and progression and the highly metastatic nature of lung cancer are of great concern... see publication
20/04/2022
Berberine Inhibits FOXM1 Dependent Transcriptional Regulation of POLE2 and Interferes With the Survival of Lung Adenocarcinoma.
Ni L, Sun P, Fan X, Li Z, Ren H, Li J.
Front Pharmacol. 2021. doi: 10.3389/fphar.2021.775514.
Background: Berberine is one of the most interesting and promising natural anticancer drugs. POLE2 is involved in many cellular functions such as DNA replication and is highly expressed in a variety of cancers. However, the specific molecular mechanism... see publication
25/03/2022
APR-246-The Mutant TP53 Reactivator-Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells.
McCubrey JA, Abrams SL, Steelman LS, Cocco L, Ratti S, Martelli AM, Lombardi P, Gizak A, Duda P.
Biomolecules. Feb 2022.
Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer. In ~75% of PDAC, the tumor suppressor TP53 gene is mutated. Novel approaches to treat cancer involve compounds called mutant TP53 reactivators. They interact with... see publication
25/03/2022
Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53.
Abrams SL, Akula SM, Steelman LS, Follo ML, Cocco L, Ratti S, Martelli AM, Libra M, Falzone L, Candido S, Montalto G, Cervello M, Lombardi P, McCubrey JA.
Adv Biol Regul. Jan 2022.
Approaches to improve pancreatic cancer therapy are essential as this disease has a very bleak outcome. Approximately 80% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDAC). A key regulatory gene frequently mutated (∼75%) in PDAC... see publication
31/08/2021
An insight into the medicinal attributes of berberine derivatives: A review.
Gaba S, Saini A, Singh G, Monga V.
Bioorg Med Chem. 05 2021.
In the last few decades, traditional natural products have been the center of attention for the scientific community and exploration of their therapeutic abilities is proceeding perpetually. Berberine, with remarkable therapeutic diversity, is a plant... see publication
28/05/2020
Enhanced Clearance of Neurotoxic Misfolded Proteins by the Natural Compound Berberine and Its Derivatives.
Rusmini P, Cristofani R, Tedesco B, Ferrari V, Messi E, Piccolella M, Casarotto E, Chierichetti M, Cicardi ME, Galbiati M, Geroni C, Lombardi P, Crippa V, Poletti A.
Int J Mol Sci. May 2020.
Accumulation of misfolded proteins is a common hallmark of several neurodegenerative disorders (NDs) which results from a failure or an impairment of the protein quality control (PQC) system. The PQC system is composed by chaperones and the degradative... see publication
10/03/2020
Asbestos, a health problem. How can we get it out of the buildings?
The Association of Quantity Surveyors, Technical Architects and Building Engineers of Barcelona (Caateeb), within its "Construction Dialogues" cycles, warned last Monday of the risk to public health posed by asbestos and the need for the Administration to draw up a work plan to remove products containing this carcinogenic mineral..
Our CEO, Dr. Carme Plasencia, the pulmonologist Josep Tarrés, and the engineer Lara Trujillo have participated in this debate in which they have underlined the importance of "making the public aware of the danger it represents", for the population..
01/10/2019
Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence
Zhang F, Jia Y, Zheng X, Shao D, Zhao Y, Wang Z, Dawulieti J, Liu W, Sun M, Sun W, Pan Y, Cui L, Wang Y, He K, Zhang M, Li J, Dong WF, Chen L.
Acta Biomater. Sep 2019.
Despite the rapid progress which has been made in hepatocellular carcinoma (HCC) chemotherapeutics, recurrence of liver cancer still remains a barrier to achieve satisfying prognosis. Herein, we aimed to decipher the role of berberine (BER) in chemotherapy-exacerbated... see publication
10/09/2019
Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells.
Abrams SL, Follo MY, Steelman LS, Lertpiriyapong K, Cocco L, Ratti S, Martelli AM, Candido S, Libra M, Murata RM, Rosalen PL, Montalto G, Cervello M, Gizak A, Rakus D, Mao W, Lombardi P, McCubrey JA.
Adv Biol Regul. Jan 2019.
Berberine (BBR) is a common nutraceutical consumed by millions worldwide. BBR has many different effects on human health, e.g., diabetes, diarrhea, inflammation and now more recently it has been proposed to have potent anti-cancer effects. BBR has... see publication
10/09/2019
Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells
Akula SM, Candido S, Libra M, Abrams SL, Steelman LS, Lertpiriyapong K, Ramazzotti G, Ratti S, Follo MY, Martelli AM, Murata RM, Rosalen PL, Bueno-Silva B, Matias de Alencar S, Montalto G, Cervello M, Gizak A, Rakus D, Mao W, Lin HL, Lombardi P, McCubrey JA.
Adv Biol Regul. Aug 2019.
Pancreatic cancer is devastating cancer worldwide with few if any truly effective therapies. Pancreatic cancer has an increasing incidence and may become the second leading cause of death from cancer. Novel, more effective therapeutic approaches are... see publication
01/07/2019
Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells-Power of nutraceuticals
McCubrey JA, Abrams SL, Lertpiriyapong K, Cocco L, Ratti S, Martelli AM, Candido S, Libra M, Murata RM, Rosalen PL, Lombardi P, Montalto G, Cervello M, Gizak A, Rakus D, Steelman LS.
Adv Biol Regul. Jan 2018.
Over the past fifty years, society has become aware of the importance of a healthy diet in terms of human fitness and longevity. More recently, the concept of the beneficial effects of certain components of our diet and other compounds, that are consumed... see publication
01/07/2019
Role of 13-(di)phenylalkyl berberine derivatives in the modulation of the activity of human topoisomerase IB.
Vieira S, Castelli S, Falconi M, Takarada J, Fiorillo G, Buzzetti F, Lombardi P, Desideri A.
Int J Biol Macromol. 2015.
Topoisomerases IB are anticancer and antimicrobial targets whose inhibition by several natural and non-natural compounds has been documented. The inhibition effect by berberine and some 13-(di)phenylalkyl berberine derivatives has been tested towards... see publication
01/07/2019
Multiple effects of berberine derivatives on colon cancer cells.
Guamán Ortiz LM, Tillhon M, Parks M, Dutto I, Prosperi E, Savio M, Arcamone AG, Buzzetti F, Lombardi P, Scovassi AI.
Biomed Res Int. 2014.
The pharmacological use of the plant alkaloid berberine is based on its antibacterial and anti-inflammatory properties; recently, anticancer activity has been attributed to this compound. To exploit this interesting feature, we synthesized three berberine... see publication
01/07/2019
Berberine acts as a natural inhibitor of Wnt/β-catenin signaling--identification of more active 13-arylalkyl derivatives.
Albring KF, Weidemüller J, Mittag S, Weiske J, Friedrich K, Geroni MC, Lombardi P, Huber O.
Biofactors 2013.
Aberrant activation of the canonical Wnt/β-catenin signaling pathway has been reported for numerous tumors of different origins. In most cases, mutations in components of the Wnt signaling pathway or in β-catenin itself were detected which ultimately... see publication
01/07/2019
Antitumor effect of novel berberine derivatives in breast cancer cells.
Pierpaoli E, Arcamone AG, Buzzetti F, Lombardi P, Salvatore C, Provinciali M.
Biofactors 2013.
Breast cancer is the most common malignancy and the most common cause of cancer death in elderly women. Chemoprevention with dietary compounds and their synthetic analogs has emerged as an attractive strategy to prevent carcinogenic progression to... see publication
01/07/2019
Berberine: new perspectives for old remedies.
Tillhon M, Guamán Ortiz LM, Lombardi P, Scovassi AI.
Biochem Pharmacol. 2012.
Chemical compounds derived from plants have been used since the origin of human beings to counteract a number of diseases. Among them, the natural isoquinoline alkaloid berberine has been employed in Ayurvedic and Chinese Medicine for hundreds of... see publication
